The incidence of people under 30 developing melanoma is increasing faster than any other demographic group, soaring by 50 percent in young women since 1980. Melanoma primarily affects individuals in the prime years of life and is the most common form of cancer for young adults 25-29 years old and the second most common cancer in adolescents and young adults 15-29 years old. Although melanoma is most common in Caucasians, melanoma can strike men and women of all ages, all races and all skin types.“There has been a dramatic increase in the number of melanoma cases the world over in the past few decades. But what’s most important is not the rise in the number of cases, but that with early detection, it’s curable with a 90 to 95 percent success rate,” explains Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We see great potential in MelApp becoming part of the monthly skin self-exams recommended by The National Cancer Institute and the American Academy of Dermatology.” MelApp by Health Discovery Corporation launches with a special limited time introductory price of $1.99 and is currently available in the iTunes App Store. More complete details about the mobile health app can be found at http://www.melapp.net. If you are a physician who diagnoses and treats melanoma, and would like to become a subscribed member of our physician referral network, please contact us at email@example.com. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.